Forest Laboratories, Inc. and Cypress Bioscience, Inc. today announced that Savella (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S. FDA for the management of fibromyalgia.
The details can be read here.
No comments:
Post a Comment